<DOC>
	<DOC>NCT00550238</DOC>
	<brief_summary>To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.</brief_summary>
	<brief_title>A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Pimavanserin</mesh_term>
	<criteria>Subject has completed the treatment period of a previous blinded study of pimavanserin The subject is willing and able to provide consent Caregiver is willing and able to accompany the subject to all visits Subject has current evidence of a serious and or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic or other medical disorder Subject is judged by the Investigator to be inappropriate for the study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Parkinson's Disease Psychosis</keyword>
</DOC>